Clinical trials for Lung cancer

281 currently recruiting clinical trials
Phase 3 Lung cancer #NCT06899126 #2024-515658-26-00
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic HER2 PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive
ALK BRAF EGFR HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1 Targeted therapy Antibody Drug Conjugates (ADC)
4 recruiting sites
Daiichi Sankyo
Phase 3 Lung cancer #NCT06312137 #2023-508012-35-00
NSCLC (Non-Small Cell Lung Cancer) Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive
ALK
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT05984277 #2023-503298-39-00
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive
ALK EGFR ROS-1
1 recruiting site
AstraZeneca
Phase 3 Lung cancer #NCT05215340 #2023-507933-12-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK BRAF EGFR MET NTRK-1/2/3 RET ROS-1 Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC)
11 recruiting sites
Daiichi Sankyo
Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive
15 recruiting sites
Summit Therapeutics
Phase 3 Lung cancer #NCT04613596 #2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1 Systemic Treatment-Naive Targeted therapy
31 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lung cancer #NCT06765109 #2024-517553-26-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ALK None Systemic Treatment-Naive
BRAF EGFR HER2 HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1 Targeted therapy
11 recruiting sites
Nuvalent Inc.